Medical Device Pivotal Study to Injection With SkinPlus-HYAL Implant Lidocaine vs RESTYLANE Lidocaine in of Nasolabial Folds

Inclusion Criteria: * Men and women 19 years of age or older * Seeking temporary improvement of bilateral nasolabial folds, with a Wrinkle Severity Rating Scale (WSRS) score of 3 or 4 (does not have to be the same on both sides) * Agrees to discontinue all dermatologic procedures or treatments (fillers, botulinum toxin, laser treatments, chemical peels, surgery for cosmetic purposes, etc.) other than investigational device application, including facial wrinkle improvement * Able to understand and follow instructions and able to participate in all periods of the investigation * Made a voluntary decision to participate in this investigation and gave written informed consent Exclusion Criteria: * Took antithrombotic agents (except low-dose aspirin (100 mg, maximum 300 mg/day)) from 2 weeks before to 2 weeks after application of the investigational device; took vitamin E formulations or NSAID formulations from 1 week before to 1 week after application * History of bleeding disorder in the past or at the time of screening * CaHA (Calcium Hydroxyapatite) or PLLA (Poly L-Lactide) filler treatment at the site of application of the investigational medical device within 1 year before the screening date * Has used or intends to use topical agents (steroids, retinoids: medicines only, excluding cosmetics) on the facial area within 4 weeks before the screening date or during the clinical trial period (however steroid ointments for therapeutic purposes may be used for a short period of time within 14 consecutive days). * Used immunosuppressants, chemotherapeutic agents, or systemic corticosteroids within 12 weeks before the screening date. * Received any anti-wrinkle or acne scar treatment within 24 weeks before the screening date. * Received dermabrasion, skin resurfacing, or cosmetic surgery (including botulinum toxin injections) to the facial area within 24 weeks before the screening date * Permanent skin augmentation implants such as hardened gel (Softform) or silicone in the facial area * Skin diseases or wound infections in the facial area that would affect this investigation * History of autoimmune disease * Hypersensitivity to sodium hyaluronate * History of streptococcal disease * History of anaphylaxis or severe multiple allergies * History of hypertrophic scars, hyperpigmentation or keloids * Hypersensitivity to lidocaine or other amide local anesthetics * Coagulation disorders * Clinically significant disorders of the cardiovascular, digestive, respiratory, endocrine, or central nervous systems or a psychiatric illness that significantly affects this investigation * Participated in another clinical investigation within 30 days before the screening date and received/applied an investigational drug/investigational medical device * Female subjects of childbearing potential who do not agree to use a medically acceptable method of contraception\* until 48 weeks after application of the investigational medical device in this investigation. (\*Medically accepted methods of contraception include: condoms, oral contraception continued for at least 3 months, use of injectable or insertable contraceptives, intrauterine contraceptive devices, etc.) * Pregnant or lactating women * Used steroid medication for therapeutic purposes (immune diseases, musculoskeletal diseases, etc.) within 4 weeks prior to enrollment in the investigation, or plans to use steroid medication during the investigation period * Used or intends to use functional cosmetics for wrinkle improvement within 4 weeks before participation in the investigation or during the investigation period * In addition to the above, those who have clinical significant findings that are considered inappropriate for this investigation by the principal investigator or personnel in charge, based on medical judgment.